GCPII variants, paralogs and orthologs

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The Glutamate carboxypeptidase II (GCPII) protein family exhibits varied tissue distribution and functions, with limited exploration of its members.
• While GCPII is well-studied, its splice variants, paralogs, and homologs, including GCPIII (NAALADase II), remain largely uncharacterized.
• GCPII splice variants show differential expression correlating with prostate cancer progression and prognosis.

Purpose of the Study:

• To highlight the importance of molecular characterization of the GCPII protein family.
• To underscore the potential of GCPII homologs, like GCPIII, as pharmaceutical targets.
• To emphasize the need for understanding GCPII's biological roles both within and outside the nervous system.

Main Methods:

• Review of existing literature on GCPII, its splice variants, paralogs, and homologs.
• Analysis of differential gene expression data related to GCPII variants in prostate cancer.
• Exploration of the enzymatic activity and potential therapeutic applications of GCPII family members.

Main Results:

• GCPII splice variants are implicated in prostate cancer progression and patient prognosis.
• GCPIII (NAALADase II) shows potential as a therapeutic target, possibly by compensating for GCPII deficiency.
• The biological significance of the broader GCPII family, beyond the nervous system, requires further investigation.

Conclusions:

• Detailed molecular characterization of the GCPII family is essential.
• GCPII inhibitors hold therapeutic potential, alongside understanding the roles of paralogs and homologs.
• Further research is needed to elucidate the complete biological functions and therapeutic relevance of the GCPII protein family.